A phase 3 study with dalpiciclib reinforces the efficacy of CDK4/6 inhibitors in select patients with metastatic breast cancer; with several such inhibitors available, more evidence is needed to help guide treatment decisions.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Zheng, J. et al. PLoS One 15, e0233571 (2020).
Long, F. et al. Cancer Sci. 110, 1420–1430 (2019).
Xu, B. et al. Nat. Med. https://doi.org/10.1038/s41591-021-01562-9 (2021).
Turner, N. C. et al. N. Engl. J. Med. 379, 1926–1936 (2018).
Slamon, D. J. et al. N. Engl. J. Med. 382, 514–524 (2020).
Sledge, G. W. et al. JAMA Oncol. 6, 116–124 (2020).
Cortes, J. et al. CA Cancer J. Clin. 70, 105–124 (2020).
O’Leary, B. et al. Nat. Commun. 9, 896 (2018).
Prat, A. et al. J. Clin. Oncol. 39, 1458–1467 (2021).
Ogata, R. et al. Breast Cancer 28, 206–215 (2021).
O’Leary, B. et al. Cancer Discov. 8, 1390–1403 (2018).
Llombart-Cussac, A. et al. Ann. Oncol. 30, v141 (2019).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
J.P.-G. reports consulting or advisory service for Roche, Daichii Sankyo, AstraZeneca, Lilly and Seattle Genetics; and travel, accommodation and expenses from Roche. J.C. reports consulting or advisory service for Roche, Celgene, Cellestia, AstraZeneca, Seattle Genetics, Daiichi Sankyo, Erytech, Athenex, Polyphor, Lilly, Merck Sharp & Dohme, GlaxoSmithKline, Leuko, Bioasis, Clovis Oncology, Boehringer Ingelheim, Ellipses, Hibercell, BioInvent, Gemoab and Gilead; honoraria from AstraZeneca, Roche, Novartis, Celgene, Eisai, Pfizer, Samsung Bioepis, Lilly, Merck Sharp & Dohme and Daiichi Sankyo; research funding to the International Breast Cancer Center from Roche, Ariad pharmaceuticals, AstraZeneca, Baxalta/Servier Affaires, Bayer Healthcare, Eisai, F. Hoffman-La Roche, Guardanth Health, Merck Sharp & Dohme, Pfizer, Piqur Therapeutics, Puma C and Queen Mary University of London; stock, patents and intellectual property with MedSIR; and travel, accommodation and expenses from Roche, Novartis, Eisai, Pfizer and Daiichi Sankyo. Antonio Llombart-Cussac reports consulting or advisory service for AstraZeneca, Celgene, Novartis, Pfizer, Roche, Eli Lilly and TESARO; expert testimony for AstraZeneca and Sanofi; research funding from Eisai, Roche, Pfizer, Eli Lilly, Merck Sharp & Dohme, Eli Lilly and Pierre Fabre; stock, patents and intellectual property with MedSIR; and travel, accommodation and expenses from Roche, Celgene, Pfizer, GE Healthcare and Eli Lilly.
Rights and permissions
About this article
Cite this article
Perez-Garcia, J.M., Cortes, J. & Llombart-Cussac, A. CDK4/6 inhibitors in breast cancer: spotting the difference. Nat Med 27, 1868–1869 (2021). https://doi.org/10.1038/s41591-021-01570-9
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41591-021-01570-9
